Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LP-184 · 1 trial · 7 indications
| Arm | Type | Description |
|---|---|---|
| Master Protocol | EXPERIMENTAL | A phase 1/2 dose escalation and cohort expansion study of LP-184 in patients with advanced or metastatic solid tumors. A BOIN design will be used to evaluate the safety of LP-184, determine the MTD, and identify the RP2D. Patients who meet all eligibility criteria will be enrolled to receive treatment with LP-184 at a dose determined based on the available cohort at the time of each patient's enrollment. Patients will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. |
| Supplement A | EXPERIMENTAL | Phase 1b/2 Expansion cohort of participants with triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma (PDAC) or other solid tumours with known DDR genomic alterations to determine the optimal dose/RP2D and to obtain preliminary estimates of clinical activity. |
| Supplement C | EXPERIMENTAL | Phase 1b/2 Expansion cohort of participants with Hormone Receptor (HR)-Negative and HER2-Negative Breast Cancer (TNBC) to evaluate the safety, tolerability and clinical activity of LP-184 in combination with olaparib |
| Supplement D | EXPERIMENTAL | Phase 1b/2 Expansion cohort of participants with KEAP1 and/or STK11-mutated and programmed cell death ligand-1 (PD-L1)-low NSCLC to evaluate the safety, tolerability and clinical activity of LP-184 in combination with nivolumab and ipilimumab in . |
| Name | Type | Description |
|---|---|---|
| LP-184 | DRUG | LP-184 is a small molecule alkylating agent causing tumor cell death through DNA damage. |
| Olaparib | DRUG | A poly (ADP-ribose) polymerase (PARP) inhibitor that impairs homologous recombination (HR) dependent DNA damage repair by trapping PARP1/2 on DNA, leading to synthetic lethality in BRCA1/2-deficient cells. |
| Nivolumab & Ipilimumab | DRUG | Nivolumab is monoclonal antibody and classified as an immune checkpoint inhibitor. By blocking the PD-1 receptor on the surface of T cells, Nivolumab restores immune cells' ability to recognize and attack cancer cells. Ipilimumab is monoclonal antibody and classified as an immune checkpoint inhibitor. By blocking the CTLA4 protein on the surface of T cells, Ipilimumab activates T-cells and allows T-cells to attack cancer cells. |
Patient Inclusion Criteria: 1. ≥18 years of age at the time of consent 2. Provided signed written ICF and voluntary consent prior to any mandatory study-specific procedures, sampling, and analyses. 3. Have a histologically or cytologically documented advanced solid tumor that has relapsed from or i...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
LP-184 is an investigational small molecule being developed for the treatment of advanced solid tumors, including metastatic solid tumors, glioblastoma (GBM), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and pancreatic adenocarcinoma. It is also being studied in patients with DDR gene mutations.
LP-184 is being developed by Lantern Pharma Inc. (NASDAQ: LTRN), a biopharmaceutical company focused on oncology. The drug is currently in Phase 1 clinical development for advanced solid tumors.
LP-184 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 study is currently active but not recruiting participants.
LP-184 is being evaluated in a Phase 1 clinical trial with the identifier NCT05933265, titled "Study of LP-184 in Patients With Advanced Solid Tumors." The trial is active but not recruiting, with an estimated enrollment of 64 participants in the United States.
No alternative names for LP-184 have been disclosed. It is referred to solely as LP-184 in clinical trial records and by its developer, Lantern Pharma Inc.